Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties in recent years. Initially met with much skepticism, MSC immunomodulation has now been well reproduced across tissue sources and species to be clinically relevant. This has opened up the use of these versatile cells for application as 3rd party/allogeneic use in cell replacement/tissue regeneration, as well as for immune- and inflammation-mediated disease entities. Most surprisingly, use of MSCs for in immune-/inflammation-mediated diseases appears to yield more efficacy than for regenerative medicine, since engraftment of the exogenous cell does not appear necessary. In this review, we focus on this non-traditional clinical use of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.

Related collections

Most cited references 84

Record: found
Abstract: not found
Article: not found

Inflammatory bowel disease.

Clara Abraham, Judy H Cho, Peter Moses (2009)

0 comments Cited 840 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Katarina Le Blanc, Ida Rasmusson, Berit Sundberg … (2004)

Adult bone-marrow-derived mesenchymal stem cells are immunosuppressive and prolong the rejection of mismatched skin grafts in animals. We transplanted haploidentical mesenchymal stem cells in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver. Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo.

0 comments Cited 656 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Amelia Bartholomew, Cord Sturgeon, Mandy Siatskas … (2002)

Mesenchymal stem cells (MSCs), multipotential cells that reside within the bone marrow, can be induced to differentiate into various components of the marrow microenvironment, such as bone, adipose, and stromal tissues. The bone marrow microenvironment is vital to the development, differentiation, and regulation of the lymphohematopoietic system. We hypothesized that the activities of MSCs in the bone marrow microenvironment might also include immunomodulatory effects on lymphocytes. Baboon MSCs were tested in vitro for their ability to elicit a proliferative response from allogeneic lymphocytes, to inhibit an ongoing allogeneic response, and to inhibit a proliferative response to potent T-cell mitogens. In vivo effects were tested by intravenous administration of donor MSCs to MHC-mismatched recipient baboons prior to placement of autologous, donor, and third-party skin grafts. MSCs failed to elicit a proliferative response from allogeneic lymphocytes. MSCs added into a mixed lymphocyte reaction, either on day 0 or on day 3, or to mitogen-stimulated lymphocytes, led to a greater than 50% reduction in proliferative activity. This effect could be maximized by escalating the dose of MSCs and could be reduced with the addition of exogenous IL-2. In vivo administration of MSCs led to prolonged skin graft survival when compared to control animals: 11.3 +/- 0.3 vs 7 +/- 0. Baboon MSCs have been observed to alter lymphocyte reactivity to allogeneic target cells and tissues. These immunoregulatory features may prove useful in future applications of tissue regeneration and stem cell engineering.

0 comments Cited 288 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

B. Linju Yen: +037-246-166 , blyen@nhri.org.tw

Journal

Journal ID (nlm-ta): J Biomed Sci

Journal ID (iso-abbrev): J. Biomed. Sci

Title: Journal of Biomedical Science

Publisher: BioMed Central (London )

ISSN (Print): 1021-7770

ISSN (Electronic): 1423-0127

Publication date (Electronic): 4 November 2016

Publication date PMC-release: 4 November 2016

Publication date Collection: 2016

Volume: 23

Electronic Location Identifier: 76

Affiliations

[1 ]Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, Zhunan, 35053 Taiwan

[2 ]Graduate Institute of Life Sciences, National Defense Medical Center (NDMC), Taipei, Taiwan

[3 ]Department of Ob/Gyn, National Taiwan University Hospital & College of Medicine, National Taiwan University, Taipei, Taiwan

[4 ]National Institute of Cancer Research, NHRI, Tainan, Taiwan

[5 ]Graduate Institute of Microbiology and Immunology, NDMC, Taipei, Taiwan

[6 ]Graduate Institute of Basic Medical Sciences, China Medical College, Taichung, Taiwan

Article

Publisher ID: 289

DOI: 10.1186/s12929-016-0289-5

PMC ID: 5095977

PubMed ID: 27809910

SO-VID: 8af56d5f-05ed-4965-a54b-22b2e26d3589

License:

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

History

Date received : 23 June 2016

Date accepted : 12 October 2016

Funding

Funded by: FundRef http://dx.doi.org/10.13039/501100004663, Ministry of Science and Technology, Taiwan;

Award ID: MOST-104-2321-B-400-021

Award ID: MOST-104-2314-B-400-002

Award Recipient : B. Linju Yen

Funded by: FundRef http://dx.doi.org/10.13039/501100004737, National Health Research Institutes;

Award ID: CS-105-PP-06

Award Recipient : B. Linju Yen

Custom metadata

ScienceOpen disciplines: Molecular medicine

Keywords: mesenchymal stem cells,human,immunomodulation,inflammation,clinical trials,autoimmune disease,organ transplantation and rejection,stem cell therapy

Data availability:

ScienceOpen disciplines: Molecular medicine

Keywords: mesenchymal stem cells, human, immunomodulation, inflammation, clinical trials, autoimmune disease, organ transplantation and rejection, stem cell therapy

Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials

Read this article at

Abstract

Related collections

Universal stem cells

Most cited references 84

Inflammatory bowel disease.

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 178

Cited by 140

Most referenced authors 4,105